What type of study is this?

September 5, 2025Open Access

Supplementary Figure S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

MMMegharani MahajanTexas A&M University – San Antonio ASAlondra L. Rodriguez SanchezThe University of Texas Health Science Center at San Antonio SJSridharan JayamohanThe University of Texas Health Science Center at San Antonio

Key Points

High MDK gene expression is linked to poor survival in breast cancer patients.
Expression analysis included data from 403 normal and 1097 breast cancer samples.
Survival analysis utilized patient data from the Xena Functional Genomics platform.
Findings suggest that MDK may be a promising therapeutic target in triple-negative breast cancer.

Abstract

Supplementary Figure S1: A. Boxplots of MDK gene expression in normal (n = 403) and BC tumor (n = 1097) gene array data (https://tnmplot.com/analysis/). B, Expression of MDK in breast invasive carcinoma based on BC subclasses. C, Expression of MDK in major subclasses of TNBC (https://ualcan.path.uab.edu/.). D, Survival analysis using Xena Functional Genomics Explorer Breast Cancer (Chin 2006) data set shows association of high MDK gene expression with poor survival in BC patients.

KI fragen

Bookmark

View Full Paper